Analyst Consensus ?
ConsensusBuy16 ratings
Bullish1381.3%
Neutral212.5%
Bearish16.2%
West Pharmaceutical Services, Inc. · WST · FY2024 Q3 · Calendar Q4 2024
West Pharma Raises 2024 Outlook as Destocking Stabilizes
West Pharma's raised outlook and resilient demand in biologics, GLP-1 contract manufacturing and wearable injection devices support a constructive operating trajectory. The case still depends on destocking normalization, mix improvement and execution of new capacity and automation.
Reported Before market openNYSEHealthcare
$27.60B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.85
Consensus $1.50
EPS surprise
+23.3%
Reported versus consensus
Reported revenue
$746.9M
Consensus $740.0M
Revenue surprise
+0.9%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+15.4%
Event window
SPY move
+0.2%
Same window
Abnormal move
+15.2%
Stock minus SPY
Volume
3.6×
Versus trailing sessions
Subsequent drift
-3.0%
Up to 20 sessions
WSTSPY benchmark
Ask FN2 about WST FY2024 Q3
Transcript, numbers and history already loaded
Why did WST rise 15.4% after beating EPS estimates in FY2024 Q3?What changed in WST's guidance and outlook in FY2024 Q3?Give me the bull and bear case for WST after FY2024 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management raised full-year 2024 sales and adjusted EPS guidance, citing stabilizing pharma destocking and growth in biologics and wearable devices. The Phoenix SmartDose facility received FDA approval for commercial manufacturing and began ramp-up, while generic-customer destocking remained a constraint.
Guidance delta
Full-year 2024 sales guidance rose to $2.875-$2.905 billion from $2.87-$2.90 billion; adjusted EPS guidance rose to $6.55-$6.75 from $6.35-$6.65.
Key takeaways
- Q3 revenue was $746.9 million, while adjusted EPS exceeded the supplied estimate.
- Management raised full-year 2024 sales and adjusted EPS guidance despite a modest organic decline.
- Pharma destocking appears to be stabilizing, although generic-customer pressure may persist into 2025.
- Growth plans center on biologics, GLP-1 contract manufacturing and wearable self-injection devices.
Management priorities
- Ramp Phoenix SmartDose manufacturing after FDA approval for commercial production.
- Build capacity at Grand Rapids and Dublin for GLP-1 devices and contract manufacturing.
- Scale automation and improve manufacturing efficiency to support margin recovery.
Follow WST with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$394.73Current
$295Low
$372Average
$447High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 27, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| TD Cowen | Buy | Buy | Maintain | Oct 13, 2026 |
| Barclays | Overweight | Overweight | Maintain | Oct 7, 2026 |
| Morgan Stanley | Overweight | Equal Weight | Upgrade | Sep 22, 2026 |
| UBS | Buy | Buy | Maintain | Sep 9, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 3, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 27, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Jul 2, 2026 |
| Stephens & Co. | Overweight | Overweight | Maintain | Jun 2, 2026 |
| B of A Securities | Buy | Buy | Maintain | Dec 13, 2024 |
| Jefferies | Buy | Hold | Upgrade | Feb 7, 2024 |
| Deutsche Bank | Hold | Hold | Maintain | Dec 14, 2022 |
| Bank of America | Underperform | Neutral | Downgrade | Dec 12, 2019 |
| William Blair | Outperform | Outperform | Maintain | Apr 23, 2019 |
| Goldman Sachs | Neutral | Neutral | Maintain | Jan 24, 2018 |
| Wells Fargo | Outperform | Outperform | Maintain | Oct 27, 2017 |
| Janney Capital | Buy | Buy | Maintain | Jan 8, 2016 |
Named analyst price targets
Upside is calculated against the persisted current price $394.73. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Luke Sergott | $440 | $372.64 | +11.5% | Oct 7, 2026 |
| Morgan Stanley | Kallum Titchmarsh | $400 | $361.73 | +1.3% | Sep 22, 2026 |
| UBS | Analyst unavailable | $415 | $338.06 | +5.1% | Sep 9, 2026 |
| Evercore ISI | Analyst unavailable | $425 | $333.12 | +7.7% | Jul 27, 2026 |
| BNP Paribas | Analyst unavailable | $447 | $353.71 | +13.2% | Jul 13, 2026 |
| Morgan Stanley | Analyst unavailable | $365 | $353.68 | -7.5% | Jul 9, 2026 |
| Evercore ISI | Daniel Markowitz | $410 | $359.27 | +3.9% | Jul 6, 2026 |
| KeyBanc | Analyst unavailable | $390 | $365 | -1.2% | Jul 2, 2026 |
| Barclays | Luke Sergott | $400 | $319.75 | +1.3% | Jun 9, 2026 |
| Morgan Stanley | Analyst unavailable | $315 | $306.39 | -20.2% | Apr 27, 2026 |
| Barclays | Analyst unavailable | $310 | $306.16 | -21.5% | Apr 27, 2026 |
| UBS | Dan Leonard | $340 | $246.6 | -13.9% | Feb 13, 2026 |
| Deutsche Bank | Analyst unavailable | $315 | $247.49 | -20.2% | Feb 13, 2026 |
| Barclays | Luke Sergott | $265 | $243.61 | -32.9% | Feb 13, 2026 |
| Jefferies | David Windley | $295 | $249.97 | -25.3% | Feb 10, 2026 |
| Evercore ISI | Daniel Markowitz | $320 | $237.88 | -18.9% | Feb 3, 2026 |
| Morgan Stanley | Analyst unavailable | $285 | $274.14 | -27.8% | Dec 1, 2025 |
| Barclays | Analyst unavailable | $325 | $293.62 | -17.7% | Oct 27, 2025 |
| UBS | Dan Leonard | $355 | $307.25 | -10.1% | Oct 24, 2025 |
| Deutsche Bank | Justin Bowers | $345 | $304.74 | -12.6% | Oct 24, 2025 |
| Evercore ISI | Daniel Markowitz | $390 | $309.28 | -1.2% | Oct 23, 2025 |
| Evercore ISI | Analyst unavailable | $350 | $268.07 | -11.3% | Oct 7, 2025 |
| Barclays | Analyst unavailable | $275 | $271.42 | -30.3% | Oct 2, 2025 |
| Redburn Partners | Jamie Clark | $311 | $257.53 | -21.2% | Sep 15, 2025 |
| Barclays | Luke Sergott | $245 | $222.68 | -37.9% | Jun 24, 2025 |
| Jefferies | David Windley | $393 | $287.85 | -0.4% | Nov 19, 2024 |
| Jefferies | David Windley | $536 | $413 | +35.8% | Feb 7, 2024 |
| Deutsche Bank | Analyst unavailable | $250 | $251.9 | -36.7% | Dec 14, 2022 |
| UBS | Analyst unavailable | $250 | $222.84 | -36.7% | Nov 30, 2022 |
Track every rating change on WST the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationWest Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies.…
Historical context
All WST earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RDY Dr. Reddy's Laboratories Limited | FY2027 Q2 · Calendar Q4 2026 | +24.0% | -0.2% | Dr. Reddy’s: margins improve as semaglutide rollout advances |
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.5% | +1.8% | Quest Diagnostics: growth broadens, but PAMA remains a headwind |
| ARGX argenx SE | FY2026 Q3 · Calendar Q4 2026 | — | -1.6% | argenx: VYVGART momentum and a broader late-stage pipeline |
| MEDP Medpace Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | +9.0% | -1.3% | Medpace: Record awards lift backlog as 2026 outlook improves |
| MOH Molina Healthcare, Inc. | FY2026 Q3 · Calendar Q4 2026 | +12.7% | +0.8% | Molina reaffirms 2026 outlook as Florida contract scales |
Latest beats and misses
Who reports nextBeat on EPS
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- RDYFY2027 Q2 · October 23, 2026+24.0% EPS-0.2% move
- SLBFY2026 Q3 · October 23, 2026+3.7% EPS+7.1% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the WST recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
- Polygon adjusted daily market bars · 2026-10-26T23:20:45.045859+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-26T23:20:45.042592+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-26. For educational purposes only; not investment advice.